Pembrolizumab Shows Further Promise for Melanoma In a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected. by Brad Jones Forward Look Tackling Drug Resistance Researchers are studing new ways to keep treatments working longer. by Stephen Ornes Survivor Profile Living in the Here and Now A metastatic melanoma survivor is hopeful but realistic as new treatments become available. by Jenny Song Forward Look Cancer Immunotherapies Continue to Make Headway Drugs that harness the power of the immune system gain new approvals. by Alexandra Goho Survivor Profile Knowing Her Options When Christina McEvoy was diagnosed with stage IV melanoma, she took the reins of her care, traveling more than 600 miles for treatment and returning home to help other melanoma survivors. by Melissa Davlin First Person Keeping Sight of Hope A survivor keeps an eye on what's ahead after a rare cancer diagnosis. by Sue Russell Cancer Talk The Ins and Outs of Tumor Testing In a session at the AACR Annual Meeting, oncologists discussed the state of cancer precision medicine—and engaged with patient advocates. by Kate Yandell The Many Faces of Patient Advocacy Advocates shared their stories and projects at the AACR Annual Meeting. by Kate Yandell Focusing on the Fundamentals National Cancer Institute director Norman “Ned” Sharpless meets with advocates and outlines areas of focus for the agency. by Marci A. Landsmann A Response to Roadblocks The Biden Cancer Initiative Colloquium gathered experts to discuss obstacles preventing access to care at the AACR Annual Meeting. by Kevin McLaughlin More Posts